We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Serum Autoantibodies Detected in Celiac Disease

By LabMedica International staff writers
Posted on 03 Apr 2013
Specific autoantibodies against actin filaments have been detected in patients suffering from celiac disease. More...


Serum autoantibodies specifically directed toward intracellular cytoskeletal actin filaments and known as antiactin antibodies, (AAA) were found to be associated with intestinal villous atrophy (IVA) in celiac disease.

Scientists at the University of Siena (Italy) retrospectively analyzed serum samples from 70 celiac disease (CD) patients of whom 41 were adults, with 31 females and 10 males, with an age range of 16-76 years; and 29 children of whom 18 were females and 11 males, whose ages ranged from 2-14 years. The study included 24 healthy controls that were also analyzed retrospectively for the presence of AAA. All celiac patients had to have antitransglutaminase (a-tTG), antiendomysial antibodies (EMA) positivity, and abnormal intestinal histology as requirements for inclusion in the study.

The investigators used a commercial indirect immunofluorescence (Eurospital; Trieste, Italy) test to detect the presence of immunoglobulin A (IgA)-AAA. The indirect immunofluorescence test used had a specificity of 100%; but the sensitivity of the test was not high at only 25.7%. There was significant association between the serum AAA which was more frequently positive in CD patients with total IVA (77.8%).

The authors concluded that IgA-AAA cannot take the place of much more sensitive tests such as a-tTG and EMA in the diagnosis of CD because of their low sensitivity. Nonetheless, these antibodies could be determined in a-tTG and/or EMA positive patients who cannot undergo an intestinal biopsy because of a severe contraindication, or in the case of negative consensus regarding endoscopy, or when the histology interpretation is difficult.

The indirect immunofluorescence commercial test with intestinal epithelial cells as substrate offers a useful method for IgA-AAA determination. Serum IgA-AAA positivity is indicative of more severe intestinal histology damage and their assay could be a real help to the clinician, especially in the complicated cases. The study was published on January 4, 2013, in the Journal of Clinical Laboratory Analysis.

Related Links:
University of Siena
Eurospital




Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.